RxDoctor Payments Data

Sameh Aziz, MD

Critical Care Medicine · Roanoke, VANPI 1205916343

Payments from drug & device makers

What this record shows

This record is dominated by education: $418 of the $682 with a category attached, or 61.3%. Actelion Pharmaceuticals US, Inc. accounts for 69.6% of it on its own, with 5 other manufacturers making up the rest.

$682in general payments, 2019–2025

Across 28 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$474
  • United Therapeutics Corporation$84
  • AstraZeneca$53
  • Sanofi$29
  • Shire North American Group Inc$25
  • Regeneron Healthcare Solutions, Inc.$17
$177,469in research payments, 2019–2025

Across 47 payments — averaging $3775.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$177K

What the payments were for

  • Food & beverage$26439%
  • Education$41861%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$682 in reported general payments places this provider in the 65th percentile of 174 critical care medicine providers in Virginia.

See all critical care medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$92,376
Medicare patients
532
Services billed
1,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orenitram ErTreprostinil Diolamine120$1,090,857
Tyvaso DpiTreprostinil42$1,003,171
OpsumitMacitentan27$363,534
AdempasRiociguat23$341,367
OpsynviMacitentan/Tadalafil11$143,417
Ambrisentan25$91,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$90,024
XolairOmalizumab20$64,953
Tadalafil20$32,708
Breo ElliptaFluticasone/Vilanterol34$26,606
Spiriva HandihalerTiotropium Bromide31$26,352
Spiriva RespimatTiotropium Bromide34$18,075
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$13,929
SymbicortBudesonide/Formoterol Fumarate41$11,863
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Opsynvi$474$506,95138 claims
AstraZenecaSymbicort, Breztri Aerosphere$53$23,46959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 174 critical care medicine providers in Virginia.

Other critical care medicine in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →